Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
August 11, 2022 04:21 ET
|
Athenex, Inc.
BUFFALO, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...
Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
August 10, 2022 16:01 ET
|
Athenex, Inc.
BUFFALO, N.Y., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...
Athenex 提供 2022 年第二季度財務業績和業務更新
July 29, 2022 04:35 ET
|
Athenex, Inc.
報告第二季度產品銷售額為 2,580 萬美元，同比增長 26%在第二季度中融資 8,500 萬美元，而 2022 上半年出售的非核心資產銷售所得收益總額為 1.25 億美元，並使高級信貸額度餘額從 1.5 億美元降至 5,750 萬美元2022 上半年用於營運活動現金比上年減少了 42%分別在 2022 年第二季度舉行的 ASTCT/CIBMTR 綜合會議和 ASGCT 年會上展示 CD19 和...
Athenex Provides Second Quarter 2022 Financial Results and Business Update
July 28, 2022 07:00 ET
|
Athenex, Inc.
Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and...
Athenex 宣佈在《Journal of Clinical Oncology》發表比較口服紫杉醇加 Encequidar 與靜脈注射紫杉醇治療轉移性乳癌患者的第 3 期研究數據
July 26, 2022 03:03 ET
|
Athenex, Inc.
紐約水牛城, July 26, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) 是一家致力於研究與開發用於治療癌症和相關疾病的新療法，並將其商業化的全球生物製藥公司。今天宣佈發表他們的手稿「一項比較口服紫杉醇加 Encequidar 與靜脈注射紫杉醇治療轉移性乳癌患者療效的開放標籤、隨機、多中心、第 III...
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology
July 25, 2022 10:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...
Athenex 將在 2022 年 7 月 28 日為 2022 年第二季度提供企業及財務更新
July 21, 2022 18:33 ET
|
Athenex, Inc.
紐約水牛城, July 22, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX) 是一家致力於研究與開發用於治療癌症和相關疾病的新療法，並將其商業化的全球生物製藥公司。今天宣佈將在 2022 年 7 月 28 日（星期四）的市場開放前，發表 2022 年第二季度的企業及財務更新。Athenex 的管理團隊將於上午 8:00 時...
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022
July 21, 2022 13:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the...
Athenex 宣佈同意將中國 API 業務出售給 TiHe Capital (Bejing) Co., Ltd.。
July 11, 2022 08:00 ET
|
Athenex, Inc.
預期銷售收益約為 1,900 萬美元公司繼續透過非核心資產獲利以擴展現金流交易收益將用於償還債務和資助營運 紐約水牛城, July 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) 是一家致力於發現、開發商業化可治療癌症和相關疾病新療法的全球生物製藥公司，今天宣佈 Athenex...
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.
July 11, 2022 08:00 ET
|
Athenex, Inc.
Expected sale proceeds of approximately $19.0 millionCompany continues to monetize non-core assets to extend cash runwayProceeds from the deal will be used to pay down debt and fund operations ...